Targacept, Inc. Logo Image

Targacept, Inc.

Most Recent Annual Report

2014 Form 10K

Targacept, Inc.

Targacept, Inc. does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

About Targacept, Inc.

Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder.

Ticker:
TRGT
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol